Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country crawled time : 12:15 save search
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
Published: 2021-11-08 (Crawled : 12:15) - biospace.com/
TYME | $0.3107 -8.21%
|
Health Technology
|
| O: -3.96%
H: 5.15%
C: 4.12%
results
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Published: 2021-11-08 (Crawled : 12:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
lung cancer therapy cancer phase 3 trial nivolumab
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published: 2021-10-05 (Crawled : 12:15) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 3.9%
H: 2.03%
C: -3.89%
treatment migraine
Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors
Published: 2021-09-14 (Crawled : 12:15) - biospace.com/
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: 0.75%
H: 1.05%
C: 0.7%
LIVN | $52.31 -0.85% -0.86% 430K
|
Health Technology
|
| O: 0.62%
H: 0.11%
C: -0.5%
HSDT | $5.01 -1.96% -2.0% 4.5K
|
Health Technology
|
| O: 3.9%
H: 0.0%
C: -3.69%
Rafael Holdings Announces $104.2 Million Private Placement
Published: 2021-08-20 (Crawled : 12:15) - biospace.com/
RFL 4 | $1.76 2.92% 0.0% 26K
|
Finance
|
| O: -8.82%
H: 6.35%
C: -4.74%
VERQUVO® (vericiguat) Approved in the European Union
Published: 2021-07-21 (Crawled : 12:15) - biospace.com/
MRK | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.2%
H: 0.18%
C: 0.09%
europe approval
Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™Jubilant HollisterStier to manufacture COVAXIN™ in the US
Published: 2021-06-15 (Crawled : 12:15) - biospace.com/
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 15.5%
H: 3.81%
C: -11.58%
covid partnership vaccine
HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO
Published: 2021-05-20 (Crawled : 12:15) - biospace.com/
HOOK | $0.7317 -4.34% -4.54% 420K
|
Health Technology
|
| O: -2.84%
H: 0.54%
C: -9.78%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.23%
H: 1.92%
C: 1.0%
treatment phase 1 cancer phase 3 phase 2
OraSure Technologies to Present at the UBS Global Healthcare Virtual Conference
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
OSUR | $5.27 0.38% 0.38% 660K
|
Health Technology
|
| O: 0.25%
H: 3.18%
C: 1.97%
conference
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license milestone
Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021
Published: 2021-05-13 (Crawled : 12:15) - biospace.com/
PTN | $1.84 -2.65% 0.05% 150K
|
Health Technology
|
| O: 0.73%
H: 3.32%
C: -3.52%
results conference
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
Published: 2021-05-13 (Crawled : 12:15) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: -15.35%
financial results pharma
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update
Published: 2021-05-13 (Crawled : 12:15) - biospace.com/
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: -0.48%
H: 1.06%
C: -9.13%
financial results results
Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
Published: 2021-04-28 (Crawled : 12:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.43%
C: -0.11%
life science
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.